Transmitted antiretroviral drug resistance has been an ongoing consideration even in patients who are treatment naive. The authors retrospectively selected all eligible patients from a US-based urban HIV clinic who had a genotypic resistance assay performed prior to the initiation of antiretroviral therapy. Clinically significant resistance was detected in 8% of assays, and was comparable when stratified by duration of time from diagnosis to genotypic resistance assay.
Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS).Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. May 4, 2006. http://www.aidsinfo.nih.gov . Accessed November 11, 2008.
2.
Huang H.-Y, Daar ES, Sax PE, et al. The prevalence of transmitted antiretroviral drug resistance in treatment-naive patients and factors influencing first-line treatment regimen selection. HIV Med. 2008;9(5):285-293.
3.
Wheeler W., Mahle K., Bodnar U., et al. Antiretroviral drug-resistance mutations and subtypes in drug-naive persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006 . Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA [Abstract 648].
4.
Palella F. Jr, Armon C., Chmiel J., et al. Improved survival associated with use of HIV susceptibility testing among HAART-experienced and therapy naive patients in the HIV Outpatient Study. Paper presented at: 14th Conference on retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA [Abstract 660].
5.
Little SJ, Holte S., Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347(6):385-394.
6.
Kuritzkes DR , Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis. 2008;197(6):867-870.
7.
Sax PE, Islam R., Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41(9):1316-1323.
8.
Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis.2008;47(2):266-285.
9.
Stanford University HIV Drug Resistance Database. http://hivdb.stanford.edu. Accessed November 11, 2008.
10.
Smith D., Moini N., Pesano R., et al. Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin Infect Dis. 2007;44(3):456-458.
11.
Shet A., Berry L., Mohri H., et al. Tracking the prevalence of transmitted antiretroviral drug-resistant decade of experience. J Acquir immune Defic Syndr. 2006; 41(4):439-446.
12.
Novak RM, Chen L., MacArthur RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis. 2005;40(3): 468-474.
13.
Johnson VA, Brun-Vezinet F., Clotet B., et al. Update of the drug resistance mutations in HIV-1: fall 2006 . Top HIV Med.2006;14(3):125-130.
